CU20090114A7 - Formulación liposomal y proceso para la preparación del mismo - Google Patents

Formulación liposomal y proceso para la preparación del mismo

Info

Publication number
CU20090114A7
CU20090114A7 CU20090114A CU20090114A CU20090114A7 CU 20090114 A7 CU20090114 A7 CU 20090114A7 CU 20090114 A CU20090114 A CU 20090114A CU 20090114 A CU20090114 A CU 20090114A CU 20090114 A7 CU20090114 A7 CU 20090114A7
Authority
CU
Cuba
Prior art keywords
preparation
same
liposomal formulation
liposome
phase transition
Prior art date
Application number
CU20090114A
Other languages
English (en)
Other versions
CU23980B1 (es
Inventor
Lan Zhang
Li Zhang
Wenmin Guo
Dongmin Shen
Yanhui Li
Caixia Wang
Jinxu Wang
Chunlei Li
Original Assignee
Shijiazhuang Pharma Group Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Pharma Group Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical Shijiazhuang Pharma Group Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CU20090114A7 publication Critical patent/CU20090114A7/es
Publication of CU23980B1 publication Critical patent/CU23980B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con una preparación farmacéutica liposómica que contiene un medicamento iónico multivalente, con un proceso para la elaboración de la preparación farmacéutica liposómica y con el uso de las mismas en el tratamiento de enfermedades, en donde el liposoma tiene un tamano aproximado de 30 a 80 nm y la bicapa fosfolipídica tiene un fosfolípido con una temperatura de transición de fase Tm mayor a la temperatura corporal, de manera tal que la temperatura de transición de fase del liposoma es mayor a la temperatura corporal.
CU2009000114A 2006-12-29 2009-06-29 Formulación liposomal y proceso para la preparación del mismo CU23980B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006101023398A CN101209243B (zh) 2006-12-29 2006-12-29 一种脂质体药物及其制备方法
PCT/CN2007/071403 WO2008080367A1 (en) 2006-12-29 2007-12-29 Liposome formulation and process for preparation thereof

Publications (2)

Publication Number Publication Date
CU20090114A7 true CU20090114A7 (es) 2011-02-24
CU23980B1 CU23980B1 (es) 2014-01-29

Family

ID=39588170

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2009000114A CU23980B1 (es) 2006-12-29 2009-06-29 Formulación liposomal y proceso para la preparación del mismo

Country Status (15)

Country Link
US (2) US20110002977A1 (es)
EP (1) EP2123260B1 (es)
JP (3) JP2010514708A (es)
KR (1) KR101126629B1 (es)
CN (1) CN101209243B (es)
AU (1) AU2007341803B2 (es)
BR (1) BRPI0720733A2 (es)
CA (1) CA2673924C (es)
CO (1) CO6190601A2 (es)
CU (1) CU23980B1 (es)
ES (1) ES2401526T3 (es)
MX (1) MX2009007089A (es)
MY (1) MY150670A (es)
RU (1) RU2494729C2 (es)
WO (1) WO2008080367A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20090136937A1 (en) 2007-05-09 2009-05-28 Coleman Matthew A Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
JPWO2010058840A1 (ja) * 2008-11-20 2012-04-19 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
JP5622719B2 (ja) 2009-03-30 2014-11-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
SI2415470T1 (sl) 2009-03-30 2016-12-30 Eisai R&D Management Co., Ltd. Liposomski sestavek
AU2014200717B2 (en) * 2009-03-30 2016-02-25 Eisai R&D Management Co., Ltd. Liposome composition
CN101897667B (zh) * 2009-05-26 2012-01-25 石药集团中奇制药技术（石家庄）有限公司 一种盐酸多柔比星脂质体注射剂及其制备工艺
CN105126179B (zh) * 2009-07-14 2018-09-25 波利皮得有限公司 持续释放药物载体组合物
CN102038640B (zh) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法
US20110274746A1 (en) * 2010-05-10 2011-11-10 Schmidt Michael A Therapeutic Liposomes and Methods For Producing and Using the Same
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US12097269B2 (en) * 2010-10-27 2024-09-24 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
EP3069785A1 (en) * 2011-10-25 2016-09-21 The University Of British Columbia Limit size lipid nanoparticles and related methods
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
IN2015DN04310A (es) * 2012-11-20 2015-10-16 Spectrum Pharmaceuticals
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
CN105143456A (zh) 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
KR101503492B1 (ko) * 2013-07-03 2015-03-19 전북대학교산학협력단 지질 및 리소좀 효소를 포함하는 리포좀 캡슐 및 그 제조방법
JP6263609B2 (ja) * 2014-04-30 2018-01-17 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2015166986A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2017035326A1 (en) 2015-08-25 2017-03-02 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
MA43183A (fr) 2015-11-02 2018-09-12 Fujifilm Corp Agent thérapeutique antitumoral contenant une composition liposomale à base de gemcitabine et kit associé
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
SG10202107836SA (en) * 2017-01-18 2021-08-30 Temasek Life Sciences Laboratory Ltd Hyperstabilized liposomes increase targeting of mitotic cells
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
CN108721644B (zh) * 2018-06-05 2021-06-08 常州金远药业制造有限公司 一种紫杉烷类药物脂质体制备方法
JP7364561B2 (ja) 2018-06-20 2023-10-18 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
CN110711178A (zh) * 2018-07-11 2020-01-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
KR20220140805A (ko) * 2020-02-10 2022-10-18 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 유방암 치료를 위한 미토산트론 염산염 리포솜의 용도
CN115279344A (zh) * 2020-03-12 2022-11-01 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN115427020A (zh) * 2020-04-13 2022-12-02 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN113876711A (zh) * 2020-07-01 2022-01-04 江苏长泰药业有限公司 一种盐酸阿霉素脂质体的制备工艺
EP4180055B1 (en) * 2020-08-07 2025-04-30 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of mitoxantrone hydrochloride liposome and pegaspargase
US20240024257A1 (en) * 2020-08-27 2024-01-25 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone
US20240058280A1 (en) * 2020-12-15 2024-02-22 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Use of mitoxantrone hydrochloride liposome
EP4324456A4 (en) 2021-04-16 2025-01-01 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME
US20240269092A1 (en) * 2021-05-28 2024-08-15 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Use of mitoxantrone hydrochloride liposome in preparation of drugs for treating advanced solid tumors
WO2023036161A1 (zh) * 2021-09-07 2023-03-16 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途
WO2023207931A1 (zh) * 2022-04-26 2023-11-02 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途
WO2024017293A1 (zh) 2022-07-20 2024-01-25 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN119677522A (zh) 2022-08-29 2025-03-21 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联用卡培他滨治疗鼻咽癌的用途
PL444722A1 (pl) * 2023-05-03 2024-11-04 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym
WO2024245378A1 (zh) 2023-06-02 2024-12-05 石药集团中奇制药技术（石家庄）有限公司 包含米托蒽醌脂质体和阿糖胞苷的药物组合物治疗急性髓系白血病的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5169635A (en) * 1989-11-17 1992-12-08 Fuji Photo Film Co., Ltd. Photoresponsive liposome
IL113135A0 (en) * 1994-03-28 1995-06-29 Daiichi Seiyaku Co Liposomes and suspensions thereof comprising multilamellar liposomes
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
DE69632859T2 (de) * 1995-04-18 2005-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verfahren zur Arzneistoffbehandlung von Liposomen Zusammensetzung
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
BR9812316A (pt) * 1997-09-16 2001-03-20 Nexstar Pharmaceuticals Inc Formulações de camptotecina lipossÈmica
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
DE69907243T2 (de) * 1998-09-16 2004-02-19 Alza Corp., Mountain View In liposomen eingeschlossene topoisomerase inhibitoren
IL147559A0 (en) * 1999-07-16 2002-08-14 Alza Corp A liposome composition having resistance to freeze/thaw damage
ES2186484B1 (es) * 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
BR0114713A (pt) 2000-10-16 2004-01-13 Neopharm Inc Formulação lipossÈmica de mitoxantrona
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US7179484B2 (en) * 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
CA2506749A1 (en) * 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
US7288396B2 (en) * 2003-09-11 2007-10-30 Kosan Biosciences Incorporated Biosynthetic gene cluster for leptomycins
RU2258530C1 (ru) * 2004-04-27 2005-08-20 Генкин Дмитрий Дмитриевич Способ профилактики и коррекции изменений кожи
UA86063C2 (ru) * 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
WO2005112957A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
CN1242740C (zh) * 2004-08-05 2006-02-22 常州太平洋药物研究所有限公司 米托蒽醌或盐酸米托蒽醌脂质体注射剂及其制备工艺
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006298844A (ja) * 2005-04-21 2006-11-02 Konica Minolta Medical & Graphic Inc リポソーム内に医薬化合物を内包するリポソーム含有製剤
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US8246983B2 (en) * 2005-09-02 2012-08-21 Northwestern University Encapsulated arsenic drugs
ES2798263T3 (es) * 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US7703945B2 (en) 2006-06-27 2010-04-27 Cree, Inc. Efficient emitting LED package and method for efficiently emitting light
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
SI2415470T1 (sl) * 2009-03-30 2016-12-30 Eisai R&D Management Co., Ltd. Liposomski sestavek
JP5480867B2 (ja) * 2011-10-07 2014-04-23 住友ゴム工業株式会社 空気入りタイヤ

Also Published As

Publication number Publication date
CA2673924C (en) 2013-10-01
EP2123260A4 (en) 2010-03-17
US20110002977A1 (en) 2011-01-06
JP6187961B2 (ja) 2017-08-30
ES2401526T3 (es) 2013-04-22
US10028913B2 (en) 2018-07-24
RU2009126983A (ru) 2011-02-10
MY150670A (en) 2014-02-28
BRPI0720733A2 (pt) 2014-01-07
CA2673924A1 (en) 2008-07-10
AU2007341803A2 (en) 2009-09-03
JP2010514708A (ja) 2010-05-06
CO6190601A2 (es) 2010-08-19
EP2123260A1 (en) 2009-11-25
AU2007341803B2 (en) 2011-08-11
EP2123260B1 (en) 2013-02-20
HK1133398A1 (en) 2010-03-26
JP2015180652A (ja) 2015-10-15
CU23980B1 (es) 2014-01-29
KR101126629B1 (ko) 2012-03-26
CN101209243B (zh) 2010-12-08
CN101209243A (zh) 2008-07-02
WO2008080367A1 (en) 2008-07-10
US20160235671A1 (en) 2016-08-18
MX2009007089A (es) 2009-10-08
AU2007341803A1 (en) 2008-07-10
JP2013177397A (ja) 2013-09-09
KR20090094043A (ko) 2009-09-02
RU2494729C2 (ru) 2013-10-10

Similar Documents

Publication Publication Date Title
CU20090114A7 (es) Formulación liposomal y proceso para la preparación del mismo
AR077764A1 (es) Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
BRPI0608297A2 (pt) composições de lipossomos
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
BR112014010467A2 (pt) pistão para um cartucho a ser cheio com um medicamento, cartucho para ser utilizado com um dispositivo de administração de fármaco e método de fabricação de um pistão
MX2016006896A (es) Microcapsulas de lipidos que comprenden preferiblemente una substancia activa lipofilica y composicion que las contiene, su metodo de preparacion y su uso en dermatolgia y cosmetica.
CR20120605A (es) Formulación tópica para un inhibidor de jak
MX2015000740A (es) Composicion de liposomas para usarse en dialisis peritoneal.
ECSP13013010A (es) Preparación de gadobutrol de alta pureza
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
CL2011000814A1 (es) Uso de auna mikacina liposomal que comprende un lipido y amikacina para preparar un medicamento util para el tratamiento de un desorden pulmonar en un paciente.
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
Alfaro‐Castellón et al. Dermoscopy distinction of eruptive vellus hair cysts with molluscum contagiosum and acne lesions
WO2008109119A3 (en) Wnt compositions and methods of use thereof
PT2459153E (pt) Composição farmacêutica ou cosmética ou dietética tendo o efeito de favorecer a pigmentação capilar
ES2879383T3 (es) Fórmulas mixtas
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
Bowe et al. Therapeutic update: acne
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
IL217519A (en) Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders
EA200970562A1 (ru) Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
ITMI20021866A1 (it) Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee.

Legal Events

Date Code Title Description
FG Grant of patent